AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support...
SKYRIZI® (risankizumab) expands its indication for children and adolescents six years of age and older with moderate to severe plaque psoriasis1 Approval was based on the pivotal Phase 3 OptIMMize-1 and OptIMMize-2 trials which include a new 55 mg pre-filled syringe to support...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.